DocUpdate is a free HIPAA-compliant digital assistant built by physicians for physicians. Their tools, including an intelligent prescribing assistant, AI medical translator for 23+ languages, and pharmaceutical concierge, are designed to give clinicians time back. More at https://docupdate.onelink.me/j4xR/DermPCP

Last issue we took apart pseudofolliculitis barbae: the shaft before the surface, inflammation before infection, pigment protection throughout.

This week we stay with pigment, and with a condition patients are still routinely told to cover rather than treat.

A patient points to a white patch on the back of the hand. It has been there a year, maybe longer. Somewhere along the way they were told it is harmless, that it is cosmetic, that nothing can be done, and that makeup is the answer.

That advice was closer to defensible fifteen years ago. It is not defensible now.

Vitiligo is an autoimmune disease in which T cells destroy melanocytes, affecting roughly 0.5% to 2% of people worldwide. There is now an FDA-approved topical therapy for repigmentation, an established phototherapy pathway, and a systemic agent under regulatory review.

Meanwhile, in the global VALIANT survey of 3,541 patients across 17 countries, 55% screened positive for moderate to severe depressive symptoms on the PHQ-9, and 59% reported frequently concealing their skin (VALIANT, JAMA Dermatol, 2023).

The distance between what is possible and what patients are told is where primary care sits.

The mistake: Framing vitiligo as an appearance issue, then moving on to the rest of the problem list.

Why it happens: It does not itch, it does not hurt, and it does not shorten life. Next to diabetes and hypertension it reads as low priority.

The evidence: The burden is measurable and large. In VALIANT, 58.7% of patients reported a diagnosed mental health condition, including anxiety in 28.8% and depression in 24.5%, and 55.0% met PHQ-9 criteria for moderate to severe depressive symptoms. Burden was consistently higher among patients with more than 5% body surface area involved, Fitzpatrick skin types IV to VI, and facial or hand lesions (VALIANT, JAMA Dermatol, 2023). Reviews of disease burden now frame vitiligo as a condition requiring treatment rather than a cosmetic variant, on the grounds that health includes psychosocial function (narrative review of burden, quality of life and stigmatization, 2024).

Practical tip: Ask one question that opens the door: does this change what you wear, where you go, or how you feel about being seen? If the answer is yes, screen with a PHQ-2. And write "autoimmune depigmenting disorder" in the chart rather than "cosmetic," because that language follows the patient into referrals and prior authorization reviews.

The mistake: Labeling any pale patch vitiligo, or dismissing true vitiligo as tinea versicolor or a fading post-inflammatory change.

Why it happens: Hypopigmentation looks similar across a long differential, and most exams happen in room light on a compressed schedule.

The evidence: Vitiligo is depigmentation, chalky white and sharply demarcated, without surface scale. The common mimics separate on features that take seconds to check. Pityriasis alba is ill-defined with fine scale, typically on the cheeks of children, and accentuates under Wood's lamp without the bright milky fluorescence and sharp borders of vitiligo. Tinea versicolor has fine scale, favors the upper trunk, fluoresces yellow-green, and is confirmed on KOH. Nevus depigmentosus is a stable congenital leukoderma. Hypopigmented mycosis fungoides deserves thought when patches are persistent and progressive in a younger patient with darker skin (StatPearls; pigmentary disorder differential references). Subtype also matters clinically: segmental disease is unilateral, tends to stabilize, and carries less autoimmune association, while non-segmental disease is bilateral, progressive, and is the form the approved topical therapy is indicated for. Activity signs are worth naming in the note, including confetti-like macules, trichrome lesions, and Koebner phenomenon, which occurs in roughly 20% to 60% of patients and points to active disease (StatPearls, vitiligo).

Practical tip: Keep a Wood's lamp within reach. Confirm depigmentation versus hypopigmentation, take a KOH when there is any scale, and document distribution and activity signs. That one line drives prognosis, referral urgency, and which treatments are even applicable.

The mistake: Making the diagnosis with no autoimmune evaluation at all, or firing off a broad autoimmune panel with no plan for the results.

Why it happens: The association is remembered vaguely, so it becomes either nothing or everything.

The evidence: In a systematic review and meta-analysis of US studies covering 10,246 adults with vitiligo, thyroid disease had the highest pooled prevalence at 14.2%, followed by psoriasis at 5.1%, rheumatoid arthritis at 3.2%, and alopecia areata at 2.7%. Certainty of evidence was highest for thyroid disease, and greater vitiligo extent was associated with rising prevalence of thyroid disease, type 1 diabetes, rheumatoid arthritis, and pernicious anemia. The authors recommend offering thyroid screening, particularly in extensive disease (Dermatol Ther (Heidelb), 2025). Thyroid autoantibody positivity runs higher still, and risk climbs with age and with non-segmental subtype. Screening intervals remain unstandardized across guidelines.

Practical tip: TSH at diagnosis is the reasonable floor, with anti-TPO where suspicion is higher: non-segmental disease, female patients, extensive involvement, or family history of autoimmunity. Repeat based on symptoms and extent rather than a fixed calendar. Keep pernicious anemia and type 1 diabetes in mind when involvement is widespread. Leave the reflexive ANA out of it.

The mistake: One tube of mid-potency corticosteroid, an open refill, no site-specific thinking, no follow-up, no referral.

The evidence: Current management is considerably wider than one tube. Topical corticosteroids and topical calcineurin inhibitors are both used off label, with calcineurin inhibitors preferred on facial and intertriginous skin where prolonged steroid use causes atrophy and telangiectasia. Ruxolitinib 1.5% cream is the only therapy specifically approved for vitiligo, indicated for non-segmental disease in patients 12 and older, applied twice daily to up to 10% body surface area, with the label noting that satisfactory response may require more than 24 weeks (FDA approval announcement; J Dermatolog Treat management review, 2026). Approval rested on the TRuE-V1 and TRuE-V2 phase 3 trials, in which ruxolitinib cream was superior to vehicle at week 24 (N Engl J Med, 2022). Narrowband UVB remains the mainstay for widespread disease, and combining phototherapy with topical tacrolimus outperformed phototherapy alone in a randomized right and left comparison, with median target lesion area reduced 42.1% on the tacrolimus side versus 29.0% on placebo. A systemic option may be close: regulatory applications for oral upadacitinib in non-segmental vitiligo were submitted to the FDA and EMA in February 2026, which would be the first systemic approval for the disease if it clears review.

Practical tip: Match the tool to the site and the extent. Calcineurin inhibitor for face and folds. Corticosteroid for limited trunk or limb disease with a defined course and a follow-up date rather than a standing refill. For non-segmental facial disease, name ruxolitinib cream explicitly, because patients are rarely told an approved option exists. For widespread, progressive, or rapidly spreading disease, refer for phototherapy and stabilization rather than cycling topicals for another year.

The mistake: Starting treatment without saying how long it takes, what early success looks like, or what happens after pigment returns.

Why it happens: The visit ends with the prescription, and repigmentation timelines are slower than almost anything else prescribed in the same clinic.

The evidence: Early perifollicular repigmentation typically appears around 2 to 3 months, with meaningful improvement often taking 6 months or longer, and the approved topical label explicitly anticipates response beyond 24 weeks. Site drives outcome: face and neck respond best because follicular melanocyte reservoirs are dense there, while acral sites, bony prominences, and mucosal surfaces respond poorly. Leukotrichia within a patch predicts a weaker response, and lesions of recent onset respond better than long-standing ones (StatPearls; repigmentation-by-body-region analyses). Relapse after successful repigmentation is common, estimated near 40% in the first year, and twice-weekly tacrolimus 0.1% applied to repigmented sites significantly reduced depigmentation in a randomized maintenance study.

Practical tip: Say the numbers out loud at the first visit. Small dots of pigment inside the patch at 2 to 3 months are the first sign it is working. Judge at 6 months, not 6 weeks. The face will outperform the hands. Then plan maintenance instead of stopping the day the patch fills in.

Vitiligo is where an outdated framing does measurable harm. The evidence that early, active disease responds better than long-standing disease means that a year of "nothing can be done" is not a neutral year. It is lost repigmentation potential.

The burden also falls unevenly. In VALIANT, patients with darker skin reported both greater quality-of-life impairment and higher rates of diagnosed mental health conditions than patients with fairer skin, which makes the reflex to call this cosmetic an equity problem as much as a clinical one. Add the practical reality that "cosmetic" in a chart note is a phrase payers read, and the framing question stops being semantic.

Primary care is usually where the first explanation of this disease happens. That explanation sets the patient's expectations for the next decade.

Name it as autoimmune, in the room and in the chart. The framing shapes the patient's expectations and the payer's decision.

Confirm before you label. Wood's lamp, KOH when there is scale, and a note on distribution, subtype, and activity signs.

Check the thyroid, skip the shotgun panel. TSH at diagnosis, anti-TPO when suspicion is higher, and a lower threshold in extensive disease.

Match treatment to site and extent. Calcineurin inhibitor on face and folds, ruxolitinib cream for non-segmental facial disease, phototherapy referral for widespread or progressive disease.

Set the timeline and plan the maintenance. First signs at 2 to 3 months, judgment at 6 months, and a maintenance plan once pigment returns.

Interested in reaching our 8,000+ subscribers?

Click here to learn more!

https://go.dermforprimarycare.com/newsletter-sponsor-lp 

We have created this FREE Guide for you:

Vitiligo is a good reminder that "not dangerous" and "not worth treating" are different claims, and that patients hear the second one when we only mean the first. More than half of patients in the largest global survey of this disease screened positive for moderate to severe depressive symptoms. That is not a cosmetic finding.

Confirm the diagnosis, check the thyroid, match the treatment to the site, and tell the patient how long it takes.

That turns a visit that used to end in reassurance into one that ends in a plan.

Have a topic you'd like us to cover? Reply to this email.

DERM Community | Derm for Primary Care Team